Concepts (275)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Parkinsonian Disorders | 10 | 2023 | 170 | 4.560 |
Why?
|
| Stroke | 20 | 2023 | 243 | 3.760 |
Why?
|
| Brain | 16 | 2023 | 1239 | 3.580 |
Why?
|
| Alzheimer Disease | 13 | 2023 | 1410 | 3.430 |
Why?
|
| Cognitive Dysfunction | 9 | 2023 | 806 | 2.650 |
Why?
|
| Intracranial Arteriosclerosis | 3 | 2022 | 41 | 2.060 |
Why?
|
| Aged, 80 and over | 28 | 2023 | 3853 | 1.760 |
Why?
|
| Aged | 43 | 2023 | 7624 | 1.760 |
Why?
|
| Cerebrovascular Disorders | 4 | 2023 | 104 | 1.700 |
Why?
|
| Female | 56 | 2023 | 13096 | 1.580 |
Why?
|
| Male | 54 | 2023 | 12609 | 1.530 |
Why?
|
| Brain Ischemia | 6 | 2020 | 61 | 1.470 |
Why?
|
| Humans | 69 | 2023 | 23144 | 1.430 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2022 | 43 | 1.410 |
Why?
|
| Dementia | 4 | 2023 | 415 | 1.350 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 186 | 1.200 |
Why?
|
| Aging | 11 | 2023 | 1175 | 1.120 |
Why?
|
| Neuropsychological Tests | 6 | 2023 | 916 | 1.050 |
Why?
|
| Hypertension | 8 | 2023 | 169 | 1.050 |
Why?
|
| Risk Factors | 24 | 2023 | 2018 | 1.050 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 61 | 1.030 |
Why?
|
| Atherosclerosis | 3 | 2023 | 46 | 1.000 |
Why?
|
| Disease Progression | 5 | 2021 | 536 | 0.960 |
Why?
|
| Dementia, Vascular | 2 | 2016 | 36 | 0.950 |
Why?
|
| Incidence | 15 | 2022 | 633 | 0.930 |
Why?
|
| tau Proteins | 4 | 2023 | 153 | 0.930 |
Why?
|
| Independent Living | 4 | 2023 | 240 | 0.890 |
Why?
|
| TDP-43 Proteinopathies | 2 | 2023 | 87 | 0.870 |
Why?
|
| Cardiovascular Diseases | 10 | 2018 | 298 | 0.860 |
Why?
|
| Stroke Rehabilitation | 2 | 2019 | 22 | 0.830 |
Why?
|
| Amyloid beta-Peptides | 4 | 2023 | 210 | 0.820 |
Why?
|
| Limbic Encephalitis | 1 | 2023 | 10 | 0.780 |
Why?
|
| Disabled Persons | 2 | 2023 | 89 | 0.780 |
Why?
|
| Motor Disorders | 1 | 2023 | 18 | 0.780 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1103 | 0.780 |
Why?
|
| Iran | 18 | 2021 | 29 | 0.720 |
Why?
|
| Executive Function | 2 | 2015 | 94 | 0.710 |
Why?
|
| Prefrontal Cortex | 3 | 2023 | 107 | 0.690 |
Why?
|
| Exercise | 4 | 2023 | 404 | 0.680 |
Why?
|
| Cerebral Hemorrhage | 7 | 2023 | 104 | 0.650 |
Why?
|
| Cohort Studies | 14 | 2022 | 1460 | 0.650 |
Why?
|
| Health Status | 2 | 2021 | 204 | 0.650 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2021 | 17 | 0.640 |
Why?
|
| White Matter | 1 | 2021 | 113 | 0.640 |
Why?
|
| Mobility Limitation | 1 | 2021 | 78 | 0.640 |
Why?
|
| Cognition | 4 | 2023 | 1024 | 0.630 |
Why?
|
| Mental Health | 1 | 2021 | 96 | 0.620 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2021 | 96 | 0.620 |
Why?
|
| Child Development | 1 | 2020 | 67 | 0.610 |
Why?
|
| Motor Activity | 3 | 2019 | 274 | 0.600 |
Why?
|
| Vision, Ocular | 1 | 2019 | 1 | 0.600 |
Why?
|
| Beta Rhythm | 1 | 2019 | 3 | 0.600 |
Why?
|
| Eyeglasses | 1 | 2019 | 3 | 0.600 |
Why?
|
| Blood Pressure | 2 | 2020 | 171 | 0.600 |
Why?
|
| Visual Perception | 1 | 2019 | 21 | 0.600 |
Why?
|
| Agnosia | 1 | 2019 | 7 | 0.600 |
Why?
|
| Brain Infarction | 1 | 2020 | 63 | 0.590 |
Why?
|
| Gait | 1 | 2023 | 385 | 0.590 |
Why?
|
| Sex Characteristics | 1 | 2018 | 91 | 0.530 |
Why?
|
| Middle Aged | 29 | 2023 | 7944 | 0.530 |
Why?
|
| Transcranial Direct Current Stimulation | 1 | 2017 | 9 | 0.520 |
Why?
|
| Upper Extremity | 1 | 2017 | 51 | 0.510 |
Why?
|
| Age Factors | 7 | 2021 | 650 | 0.510 |
Why?
|
| Autopsy | 4 | 2021 | 259 | 0.480 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2015 | 24 | 0.460 |
Why?
|
| Aspirin | 1 | 2015 | 48 | 0.450 |
Why?
|
| Parkinson Disease | 4 | 2023 | 595 | 0.430 |
Why?
|
| Triglycerides | 3 | 2022 | 54 | 0.430 |
Why?
|
| Case-Control Studies | 11 | 2023 | 486 | 0.410 |
Why?
|
| Metabolic Syndrome | 4 | 2018 | 55 | 0.390 |
Why?
|
| Receptors, Estrogen | 2 | 2023 | 62 | 0.380 |
Why?
|
| Adult | 18 | 2023 | 6945 | 0.330 |
Why?
|
| Canada | 4 | 2015 | 42 | 0.320 |
Why?
|
| Cognition Disorders | 3 | 2016 | 723 | 0.320 |
Why?
|
| Follow-Up Studies | 8 | 2020 | 1429 | 0.310 |
Why?
|
| Prospective Studies | 9 | 2023 | 1508 | 0.310 |
Why?
|
| Obesity | 4 | 2019 | 288 | 0.310 |
Why?
|
| DNA-Binding Proteins | 2 | 2023 | 231 | 0.300 |
Why?
|
| Time Factors | 4 | 2019 | 1260 | 0.300 |
Why?
|
| Waist Circumference | 4 | 2019 | 35 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 277 | 0.280 |
Why?
|
| Treatment Outcome | 6 | 2021 | 2939 | 0.260 |
Why?
|
| Recovery of Function | 2 | 2019 | 242 | 0.260 |
Why?
|
| Disability Evaluation | 2 | 2019 | 225 | 0.260 |
Why?
|
| Activities of Daily Living | 2 | 2023 | 368 | 0.250 |
Why?
|
| Language | 1 | 2006 | 57 | 0.240 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 779 | 0.230 |
Why?
|
| Neurofibrillary Tangles | 2 | 2023 | 120 | 0.230 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 276 | 0.230 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 1037 | 0.230 |
Why?
|
| Hospitalization | 1 | 2007 | 287 | 0.220 |
Why?
|
| Waist-Hip Ratio | 5 | 2019 | 12 | 0.220 |
Why?
|
| Risk Assessment | 4 | 2021 | 548 | 0.210 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2023 | 18 | 0.200 |
Why?
|
| Binge Drinking | 1 | 2023 | 9 | 0.190 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2023 | 26 | 0.190 |
Why?
|
| RNA | 1 | 2023 | 29 | 0.190 |
Why?
|
| Smoking | 3 | 2020 | 162 | 0.190 |
Why?
|
| Cerebrum | 1 | 2023 | 6 | 0.190 |
Why?
|
| Hand Strength | 1 | 2023 | 49 | 0.190 |
Why?
|
| Opium | 1 | 2022 | 1 | 0.190 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 52 | 0.190 |
Why?
|
| Cholesterol | 1 | 2022 | 60 | 0.180 |
Why?
|
| Spinal Cord | 1 | 2022 | 74 | 0.180 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2021 | 1 | 0.180 |
Why?
|
| Motor Cortex | 1 | 2021 | 16 | 0.170 |
Why?
|
| Life Style | 2 | 2020 | 167 | 0.170 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 107 | 0.170 |
Why?
|
| Migraine Disorders | 1 | 2021 | 18 | 0.170 |
Why?
|
| Ontario | 1 | 2021 | 12 | 0.170 |
Why?
|
| Potassium | 1 | 2021 | 59 | 0.170 |
Why?
|
| Sodium | 1 | 2021 | 56 | 0.170 |
Why?
|
| Sex Factors | 2 | 2020 | 398 | 0.160 |
Why?
|
| Nerve Block | 1 | 2021 | 61 | 0.160 |
Why?
|
| Movement Disorders | 1 | 2021 | 57 | 0.160 |
Why?
|
| Walking | 1 | 2023 | 235 | 0.160 |
Why?
|
| Peptides | 1 | 2021 | 89 | 0.160 |
Why?
|
| Biomarkers | 2 | 2020 | 488 | 0.160 |
Why?
|
| Psychomotor Performance | 1 | 2021 | 165 | 0.160 |
Why?
|
| Residence Characteristics | 2 | 2012 | 179 | 0.150 |
Why?
|
| Depression | 1 | 2023 | 383 | 0.150 |
Why?
|
| Apolipoproteins E | 1 | 2020 | 159 | 0.150 |
Why?
|
| Linear Models | 1 | 2020 | 201 | 0.150 |
Why?
|
| Functional Laterality | 1 | 2019 | 53 | 0.150 |
Why?
|
| Noncommunicable Diseases | 1 | 2018 | 1 | 0.140 |
Why?
|
| Heredity | 1 | 2018 | 6 | 0.140 |
Why?
|
| Pedigree | 1 | 2018 | 51 | 0.140 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 294 | 0.140 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2018 | 1 | 0.140 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 124 | 0.140 |
Why?
|
| Glycogen | 1 | 2018 | 13 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2019 | 370 | 0.140 |
Why?
|
| ROC Curve | 4 | 2022 | 120 | 0.140 |
Why?
|
| Milk | 1 | 2017 | 11 | 0.130 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 11 | 0.130 |
Why?
|
| CADASIL | 1 | 2017 | 1 | 0.130 |
Why?
|
| Research Design | 1 | 2018 | 162 | 0.130 |
Why?
|
| alpha-Synuclein | 1 | 2018 | 103 | 0.130 |
Why?
|
| Genotype | 1 | 2018 | 264 | 0.130 |
Why?
|
| Chicago | 1 | 2020 | 848 | 0.130 |
Why?
|
| Menopause | 1 | 2018 | 100 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 98 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2017 | 210 | 0.130 |
Why?
|
| Child | 1 | 2020 | 1159 | 0.120 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2016 | 5 | 0.120 |
Why?
|
| Vasodilation | 1 | 2016 | 6 | 0.120 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2016 | 5 | 0.120 |
Why?
|
| Mutation | 1 | 2018 | 329 | 0.120 |
Why?
|
| Neuropathology | 1 | 2016 | 63 | 0.120 |
Why?
|
| Methamphetamine | 1 | 2016 | 22 | 0.120 |
Why?
|
| Central Nervous System Stimulants | 1 | 2016 | 39 | 0.120 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 436 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 37 | 0.120 |
Why?
|
| Tropanes | 1 | 2015 | 1 | 0.120 |
Why?
|
| Organotechnetium Compounds | 1 | 2015 | 7 | 0.120 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 26 | 0.120 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 16 | 0.120 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 44 | 0.110 |
Why?
|
| Prediabetic State | 1 | 2014 | 2 | 0.110 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 75 | 0.110 |
Why?
|
| Heart Rate | 1 | 2014 | 104 | 0.100 |
Why?
|
| Incidental Findings | 1 | 2014 | 11 | 0.100 |
Why?
|
| Body Mass Index | 3 | 2023 | 380 | 0.100 |
Why?
|
| Memory | 1 | 2015 | 223 | 0.100 |
Why?
|
| Interviews as Topic | 2 | 2019 | 113 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 150 | 0.090 |
Why?
|
| Rural Population | 1 | 2012 | 14 | 0.090 |
Why?
|
| Quality of Life | 1 | 2016 | 566 | 0.090 |
Why?
|
| Urban Population | 1 | 2012 | 131 | 0.080 |
Why?
|
| Phenotype | 2 | 2023 | 258 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2022 | 65 | 0.070 |
Why?
|
| Logistic Models | 1 | 2010 | 356 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 596 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2022 | 2991 | 0.070 |
Why?
|
| Efferent Pathways | 1 | 2008 | 1 | 0.070 |
Why?
|
| Neural Conduction | 1 | 2008 | 11 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 802 | 0.070 |
Why?
|
| Action Potentials | 1 | 2008 | 83 | 0.070 |
Why?
|
| Age Distribution | 1 | 2007 | 69 | 0.070 |
Why?
|
| Skin | 1 | 2008 | 113 | 0.070 |
Why?
|
| Comorbidity | 2 | 2021 | 428 | 0.060 |
Why?
|
| Middle East | 2 | 2017 | 3 | 0.060 |
Why?
|
| Developing Countries | 2 | 2018 | 13 | 0.060 |
Why?
|
| Diabetes Complications | 2 | 2017 | 46 | 0.060 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 137 | 0.060 |
Why?
|
| Odds Ratio | 2 | 2017 | 225 | 0.060 |
Why?
|
| Europe | 2 | 2016 | 51 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 192 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 716 | 0.050 |
Why?
|
| Prevalence | 2 | 2016 | 380 | 0.050 |
Why?
|
| Angina, Unstable | 2 | 2014 | 9 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2014 | 13 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 21 | 0.050 |
Why?
|
| Adaptor Protein Complex 1 | 1 | 2023 | 4 | 0.050 |
Why?
|
| Adaptor Protein Complex beta Subunits | 1 | 2023 | 4 | 0.050 |
Why?
|
| Olfactory Bulb | 1 | 2023 | 12 | 0.050 |
Why?
|
| Proteome | 1 | 2023 | 23 | 0.050 |
Why?
|
| Myocardial Infarction | 2 | 2014 | 124 | 0.050 |
Why?
|
| Lewy Bodies | 1 | 2023 | 150 | 0.050 |
Why?
|
| Young Adult | 2 | 2018 | 1655 | 0.050 |
Why?
|
| Health Surveys | 2 | 2013 | 77 | 0.050 |
Why?
|
| Muscle Spasticity | 1 | 2021 | 4 | 0.040 |
Why?
|
| Triamcinolone | 1 | 2021 | 6 | 0.040 |
Why?
|
| Lidocaine | 1 | 2021 | 20 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2021 | 33 | 0.040 |
Why?
|
| Headache | 1 | 2021 | 37 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 104 | 0.040 |
Why?
|
| Potassium, Dietary | 1 | 2021 | 1 | 0.040 |
Why?
|
| Sodium, Dietary | 1 | 2021 | 6 | 0.040 |
Why?
|
| Causality | 1 | 2021 | 44 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2021 | 37 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2022 | 215 | 0.040 |
Why?
|
| Sleep | 1 | 2023 | 270 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2021 | 227 | 0.040 |
Why?
|
| Waist-Height Ratio | 1 | 2019 | 5 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2019 | 21 | 0.040 |
Why?
|
| Blood Pressure Determination | 1 | 2019 | 11 | 0.040 |
Why?
|
| Anthropometry | 1 | 2019 | 29 | 0.040 |
Why?
|
| Adiposity | 1 | 2019 | 42 | 0.040 |
Why?
|
| Physical Examination | 1 | 2019 | 87 | 0.040 |
Why?
|
| Gene-Environment Interaction | 1 | 2018 | 13 | 0.040 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2018 | 1 | 0.030 |
Why?
|
| Developed Countries | 1 | 2018 | 1 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 59 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 29 | 0.030 |
Why?
|
| Mediterranean Region | 1 | 2017 | 1 | 0.030 |
Why?
|
| Age of Onset | 1 | 2018 | 74 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 225 | 0.030 |
Why?
|
| Poverty | 1 | 2018 | 85 | 0.030 |
Why?
|
| Microvessels | 1 | 2017 | 12 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 96 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 2018 | 81 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2017 | 214 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 66 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Carotid Artery, Common | 1 | 2016 | 3 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2016 | 17 | 0.030 |
Why?
|
| Apolipoproteins B | 1 | 2016 | 2 | 0.030 |
Why?
|
| Apolipoprotein A-I | 1 | 2016 | 2 | 0.030 |
Why?
|
| Asia | 1 | 2016 | 9 | 0.030 |
Why?
|
| Africa | 1 | 2016 | 9 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 20 | 0.030 |
Why?
|
| International Cooperation | 1 | 2016 | 14 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 28 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 283 | 0.030 |
Why?
|
| China | 1 | 2016 | 45 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 19 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 162 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 60 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 22 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2016 | 79 | 0.030 |
Why?
|
| United States | 1 | 2021 | 1803 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2016 | 66 | 0.030 |
Why?
|
| Health Behavior | 1 | 2016 | 140 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2018 | 338 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 201 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 269 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 305 | 0.030 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 98 | 0.030 |
Why?
|
| Diet | 1 | 2014 | 181 | 0.020 |
Why?
|
| Rural Health | 1 | 2013 | 4 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 1877 | 0.020 |
Why?
|
| Urban Health | 1 | 2013 | 18 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2012 | 17 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 77 | 0.020 |
Why?
|
| Public Health | 1 | 2012 | 47 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 168 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2011 | 116 | 0.020 |
Why?
|
| Survival Rate | 1 | 2012 | 316 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 136 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 3289 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2008 | 46 | 0.020 |
Why?
|
| Electrophysiology | 1 | 2008 | 95 | 0.020 |
Why?
|
| Hand | 1 | 2008 | 38 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 206 | 0.020 |
Why?
|